“We are in the final stages and within a few days we will hold the proteins – the active component of the vaccine,” Dr. Chen Katz, leader of the biotechnology group at the Galilee Research Institute (MIGAL), told Reuters.
In late February, Israeli scientists at MIGAL said they might have a vaccine on the market within 90 days. The scientists there have also been working over the last four years to develop a vaccine against the infectious bronchitis virus (IBV), a coronavirus that affects chickens.
After examining the sequenced DNA of COVID-19, MIGAL researchers discovered that IBV is very genetically similar to COVID-19 and uses the same infection method. Given the fact that Israeli scientists have been working on an IBV vaccine, they could be able to develop a human vaccine for COVID-19 very quickly, Katz explained at the time. Israeli Science and Technology Minister Ofer Akunis also said in February that he had ordered the fast-track approval of the vaccine to bring it to market as soon as possible.
“Our basic concept was to develop the technology and not specifically a vaccine for this kind or that kind of virus,” Katz explained, Reuters reported. “The scientific framework for the vaccine is based on a new protein expression vector, which forms and secretes a chimeric soluble protein that delivers the viral antigen into mucosal tissues by self-activated endocytosis, causing the body to form antibodies against the virus.”
Endocytosis is a cellular process in which substances are absorbed into the cell. The material is internalized inside the cell to generate a vesicle of the ingested material.
However, Katz said, the vaccine production was slightly delayed because it took longer than expected to receive a genetic construct required for the vaccine from China due to closed airways.
According to Katz, MIGAL is currently working with regulators to ensure that the product can be tested on humans. He also noted that because the drug will be taken orally, “the quality of this kind of vaccine should be closer to food regulations than pharma regulations, or somewhere in between. We hope that we will not need to go through the complete purification process like in the drug industry, because that could delay us.”
The phase I human trials would be carried out on “young, healthy individuals” and then would then be extended to the general population, he said.
The Israel Institute for Biological Research (IIBR) also revealed on Tuesday that it had started testing a COVID-19 vaccine on rodents at its biochemical defense laboratory. Israeli Prime Minister Benjamin Netanyahu commissioned the IIBR, which is located in the central Israeli city of Ness Ziona, to help fight against the coronavirus pandemic on February 1, according to Reuters.